Literature DB >> 16697833

Predictors of success for first stage neuromodulation: motor versus sensory response.

Brian L Cohen1, Hari S G R Tunuguntla, Angelo Gousse.   

Abstract

PURPOSE: We investigated whether intraoperative motor or sensory response is more predictive of successful sacral neuromodulation using the InterStim system.
MATERIALS AND METHODS: A total of 35 patients with medically refractory frequency, urgency and urge incontinence were enrolled in the study. All patients underwent lead placement for quadripolar test stimulation under local anesthesia with intravenous sedation. Confirmation of correct lead placement was by observation of known motor and sensory responses that result from third sacral nerve stimulation. Motor and sensory responses were documented intraoperatively. Patients had a 1-week trial of stimulation, and those who had greater than 50% improvement in symptoms had placement of the implantable pulse generator. Those without at least 50% improvement in their symptoms had the quadripolar lead removed.
RESULTS: Of the 35 patients enrolled 21 had successful quadripolar test stimulation and went on to permanent implantable pulse generator placement. Of the patients who had successful quadripolar test stimulation 95% demonstrated positive intraoperative motor response whereas only 21.4% of patients with unsuccessful quadripolar test stimulation demonstrated positive motor response. If only a positive sensory response was elicited, patients had only a 4.7% chance of having a positive quadripolar test stimulation.
CONCLUSIONS: A positive quadripolar test stimulation (greater than 50% improvement in symptoms) with InterStim sacral neuromodulation is more likely when intraoperative lead placement results in positive motor response vs only sensory response.

Entities:  

Mesh:

Year:  2006        PMID: 16697833     DOI: 10.1016/S0022-5347(06)00315-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  17 in total

Review 1.  A systematic review of clinical studies of electrical stimulation for treatment of lower urinary tract dysfunction.

Authors:  Ash K Monga; Michael R Tracey; Jeyakumar Subbaroyan
Journal:  Int Urogynecol J       Date:  2012-03-17       Impact factor: 2.894

Review 2.  Selection of ideal candidates for neuromodulation in refractory overactive bladder.

Authors:  Ravi Kacker; Anurag K Das
Journal:  Curr Urol Rep       Date:  2010-11       Impact factor: 3.092

Review 3.  Current opinion: complications and troubleshooting of sacral neuromodulation.

Authors:  Paul Pettit
Journal:  Int Urogynecol J       Date:  2010-12       Impact factor: 2.894

Review 4.  Sacral nerve stimulation: neuromodulation for voiding dysfunction and pain.

Authors:  Robert D Mayer; Fred M Howard
Journal:  Neurotherapeutics       Date:  2008-01       Impact factor: 7.620

Review 5.  How does sacral modulation work best? Placement and programming techniques to maximize efficacy.

Authors:  Bastian Amend; Mahmoud Khalil; Thomas M Kessler; Karl-Dietrich Sievert
Journal:  Curr Urol Rep       Date:  2011-10       Impact factor: 3.092

Review 6.  Specific Tips for General Controversies in Sacral Neuromodulation.

Authors:  Ahmed S El-Azab; Steven W Siegel
Journal:  Curr Urol Rep       Date:  2016-11       Impact factor: 3.092

7.  [Sacral neuromodulation for refractory overactive bladder].

Authors:  Arndt van Ophoven
Journal:  Urologe A       Date:  2018-11       Impact factor: 0.639

Review 8.  Neuromodulation and the role of electrodiagnostic techniques.

Authors:  Karen L Noblett
Journal:  Int Urogynecol J       Date:  2010-12       Impact factor: 2.894

Review 9.  Sacral nerve stimulation to treat nonobstructive urinary retention in women.

Authors:  Craig V Comiter
Journal:  Curr Urol Rep       Date:  2008-09       Impact factor: 3.092

10.  Predictors of response to intradetrusor botulinum toxin-A injections in patients with idiopathic overactive bladder.

Authors:  Brian L Cohen; Daniel J Caruso; Prashanth Kanagarajah; Angelo E Gousse
Journal:  Adv Urol       Date:  2009-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.